Prednicarbate

Summary

Prednicarbate (CHEMBL1200386) is an approved small molecule (ATC D07AC18); indicated across 5 conditions including skin disorder and tinea pedis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D07AC18
• Indications: 5 conditions
• Clinical trials: 5
• Chemistry: 488.6 Da · C27H36O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200386
Name	Prednicarbate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6714002
ATC	D07AC18
Molecular formula	C27H36O8
Molecular weight	488.6
InChIKey	FNPXMHRZILFCKX-KAJVQRHHSA-N

SMILES: CCC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)OC(=O)OCC

IUPAC name: [2-[(8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate

Also known as: Dermatop, Dermatop e emollient, HOE 777, HOE-777, LAS-189961, LAS189961, NSC-760042, Prednicarbate, PREDNICARBATE COMPONENT OF LAS-41003, Prednicarbato, S 77 0777, S-77 0777

Patent coverage: 3,033 distinct patent families (12,068 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Beta-lactamase, Glucocorticoid receptor, Progesterone receptor, Androgen receptor.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR3C1	7.77	AC50	17	nM	CHEMBL_ACT_25176053
P15207	6.15	AC50	710	nM	CHEMBL_ACT_25187587
PGR	5.89	AC50	1300	nM	CHEMBL_ACT_25223205

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
skin disorder	4	MONDO:0005093	EFO:0000701
tinea pedis	2	MONDO:0005984	EFO:0007512
candidiasis	2	MONDO:0002026	MONDO:0002026
psoriasis	1	MONDO:0005083	EFO:0000676

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	3
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01020994	PHASE2	COMPLETED	Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected Eczema
NCT01096472	PHASE2	COMPLETED	Efficacy and Safety of LAS41003 in the Treatment of Inflammatory Tinea Pedis
NCT01102387	PHASE2	COMPLETED	Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida Infections
NCT03399526	PHASE1	COMPLETED	1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat
NCT00148746	Not specified	COMPLETED	Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).